Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia

被引:76
作者
Hirakata, Yoichi [1 ]
Yanagihara, Katsunori [1 ]
Kurihara, Shintaro [1 ]
Izumikawa, Koichi [1 ]
Seki, Masafumi [1 ]
Miyazaki, Yoshitsugu [1 ]
Kohno, Shigeru [1 ]
机构
[1] Nagasaki Univ, Dept Internal Med 2, Sch Med & Dent, Nagasaki 8528501, Japan
关键词
bacterial infection; community-acquired pneumonia; C-reactive protein; procalcitonin; systemic inflammatory response syndrome;
D O I
10.1016/j.diagmicrobio.2008.01.014
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Although procalcitonin (PCT) measurement has been performed in patients with infectious diseases, there are few reports on its usefulness in community-acquired pneumonia (CAP) associated with systemic inflammatory response syndrome (SIRS). We investigated 88 patients who visited the internal medicine departments of Nagasaki University Hospital, Nagasaki, Japan, and its I I affiliated hospitals in Japan because of CAP with or without SIRS. Of the 88 patients, 15 (17.0%), 43 (48.9%), and 30 (34.1%) were judged to have severe, moderate, and mild CAT respectively. Although 87 patients (98.9%) had C-reactive protein (CRP) levels exceeding 0.3 mg/dL, only 30 patients (34.1%) had PCT levels more than 0.5 ng/mL. In addition, 93.3% (28/30) of patients with mild CAP had negative PCT, and 48.3% (28/58) of patients positive for PCT had moderate or severe CAP. Our findings suggest that PCT level might be more useful for estimating CAP severity than CRP level at the 1st visit. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:170 / 174
页数:5
相关论文
共 27 条
  • [1] Aikawa Naoki, 2005, Journal of Infection and Chemotherapy, V11, P152, DOI 10.1007/s10156-005-0388-9
  • [2] HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTION
    ASSICOT, M
    GENDREL, D
    CARSIN, H
    RAYMOND, J
    GUILBAUD, J
    BOHUON, C
    [J]. LANCET, 1993, 341 (8844) : 515 - 518
  • [3] Kinetics of procalcitonin, interleukin 6 and C-reactive protein after cardiopulmonary-bypass in children
    Beghetti, M
    Rimensberger, PC
    Kalangos, A
    Habre, W
    Gervaix, A
    [J]. CARDIOLOGY IN THE YOUNG, 2003, 13 (02) : 161 - 167
  • [4] DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS
    BONE, RC
    BALK, RA
    CERRA, FB
    DELLINGER, RP
    FEIN, AM
    KNAUS, WA
    SCHEIN, RMH
    SIBBALD, WJ
    [J]. CHEST, 1992, 101 (06) : 1644 - 1655
  • [5] Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia
    Boussekey, N
    Leroy, O
    Alfandari, S
    Devos, P
    Georges, H
    Guery, B
    [J]. INTENSIVE CARE MEDICINE, 2006, 32 (03) : 469 - 472
  • [6] Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit
    Boussekey, N
    Leroy, O
    Georges, H
    Devos, P
    d'Escrivan, T
    Guery, B
    [J]. INFECTION, 2005, 33 (04) : 257 - 263
  • [7] Kinetics of procalcitonin in iatrogenic sepsis
    Brunkhorst, FM
    Heinz, U
    Forycki, ZF
    [J]. INTENSIVE CARE MEDICINE, 1998, 24 (08) : 888 - 889
  • [8] Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia
    Brunkhorst, FM
    Al-Nawas, B
    Krummenauer, F
    Forycki, ZF
    Shah, PM
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (02) : 93 - 100
  • [9] Brunkhorst FM, 2000, INTENS CARE MED, V26, pS148, DOI 10.1007/BF02900728
  • [10] Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections:: cluster-randomised, single-blinded intervention trial
    Christ-Crain, M
    Jaccard-Stolz, D
    Bingisser, R
    Gencay, MM
    Huber, PR
    Tamm, M
    Müller, B
    [J]. LANCET, 2004, 363 (9409) : 600 - 607